Catheter ablation of persistent atrial fibrillation: anatomically based circumferential pulmonary vein ablation in combination with a potential-guided segmental approach to achieve complete pulmonary vein isolation.
BACKGROUND
Catheter ablation has become the first line of therapy in patients with symptomatic, recurrent, drug-refractory atrial fibrillation. However, catheter ablation of persistent atrial fibrillation is still a challenge. Various rather complex ablation strategies exist and their results are not very favorable. Therefore, the aim of our study was to evaluate a well-defined reasonable approach to catheter ablation of persistent atrial fibrillation. The strategy consisted of a circumferential pulmonary vein ablation in combination with a potential-guided segmental approach to achieve complete pulmonary vein isolation and a linear lesion at the roof of the left atrium.


METHODS
A total of 43 patients (30 men, 13 women; mean age 55 years (SD ± 9 years)) with symptomatic persistent atrial fibrillation were enrolled in this study. All patients underwent catheter ablation of persistent atrial fibrillation using the above-mentioned approach (with the CARTO or the NAVX system). Additionally, catheter ablation of the mitral isthmus and the right atrial isthmus was performed in selected cases. In all patients, cardiac MRI or multi-detector spiral computed tomography was performed prior to the ablation procedure and a surface rendered model of the left atrium was created. After discharge, patients were scheduled for repeated visits at the arrhythmia clinic at 1, 3, 6, 9, and 12 months after the ablation procedure.


RESULTS
The ablation procedure could be performed as planned in all 43 patients. Nine patients had to undergo a repeat ablation procedure, so that a total of 52 procedures were evaluated. An additional linear lesion was created at the mitral isthmus in three patients (7%) during the initial procedure and in one patient (2.3%) during the second procedure. Catheter ablation of the right atrial isthmus was performed in 11 patients (25.6%) during the first procedure and in four additional patients during the redo procedure (9.3%). Twenty-four out of 43 patients (55.8%) experienced an arrhythmia recurrence within the first 3 months after ablation requiring an electrical cardioversion. At 1-year follow-up, analysis of a 7-day Holter monitoring revealed no evidence for an arrhythmia recurrence in 26 of 43 patients (60.5%). In nine of 43 patients (20.9%), only short episodes of paroxysmal atrial fibrillation were documented. In eight patients (18.6%), a recurrence of persistent atrial fibrillation (>48 h) was revealed by the long-term recordings. A duration of persistent atrial fibrillation >3 months was the most powerful predictor for arrhythmia recurrences at 1-year follow-up. A subgroup analysis revealed a markedly higher rate of stable sinus rhythm at 1-year follow-up in patients with a short duration of atrial fibrillation (≤ 3 months) compared to patients with a longer duration of AF (>3 months) prior to the procedure (72.0% versus 44.4%). There were no major complications.


CONCLUSIONS
Catheter ablation of persistent atrial fibrillation can be performed safely and effectively using this ablation strategy (especially in patients with short-lasting persistent atrial fibrillation (≤ 3 months)).
Medizinische Klinik III; Kardiologie und Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Tübingen, Germany. Klaus.Kettering@t-online.de
Klaus
K
Kettering
Hans-Joerg
HJ
Weig
Mathias
M
Busch
Klaus Martin
KM
Schneider
Christian
C
Eick
Slawomir
S
Weretka
Roman
R
Laszlo
Meinrad
M
Gawaz
Juergen
J
Schreieck
D001281:Atrial Fibrillation / Q000175:diagnosis* / Q000601:surgery*; D018780:Body Surface Potential Mapping / Q000379:methods*; D017115:Catheter Ablation / Q000379:methods*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011667:Pulmonary Veins / Q000601:surgery*; D025321:Surgery, Computer-Assisted / Q000379:methods*; D016896:Treatment Outcome
Pacing Clin Electrophysiol. 2006 Mar;29(3):283-9
16606396
Clin Res Cardiol. 2006 Dec;95(12):663-7
16998744
J Am Coll Cardiol. 1999 Mar 15;33(4):972-84
10091824
Circulation. 2005 Nov 15;112(20):3038-48
16275866
Circulation. 2005 Jan 18;111(2):127-35
15623542
Am J Cardiol. 2000 Nov 2;86(9A):9K-19K
11084094
Circulation. 2004 Oct 12;110(15):2090-6
15466640
Circulation. 2002 Sep 3;106(10):1256-62
12208802
J Am Coll Cardiol. 2004 Jun 2;43(11):2044-53
15172410
Pacing Clin Electrophysiol. 1998 Oct;21(10):1959-78
9793093
Circulation. 1999 Nov 16;100(20):2085-92
10562265
Pacing Clin Electrophysiol. 2008 Jun;31(6):652-9
18507536
N Engl J Med. 2006 Mar 2;354(9):934-41
16510747
Circulation. 2004 Nov 9;110(19):2996-3002
15520313
J Am Coll Cardiol. 2002 Aug 7;40(3):464-74
12142112
Circulation. 2005 Jun 7;111(22):2875-80
15927974
Clin Res Cardiol. 2009 May;98(5):285-96
19283334
Circulation. 1998 Mar 31;97(12):1176-85
9537344
Circulation. 2004 Nov 2;110(18):2797-801
15505091
J Cardiovasc Electrophysiol. 2001 Aug;12(8):900-8
11513440
J Cardiovasc Electrophysiol. 2000 Jan;11(1):2-10
10695453
J Cardiovasc Electrophysiol. 1996 Dec;7(12):1132-44
8985802